SCHEMBL2420008

SCHEMBL2420008

O=C(NCc1ccc(S(=O)(=O)N2CCC(n3nccn3)CC2)s1)c1ccc(Cl)cc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 1/20 0.68
MAPK10 P53779 1/20 0.68
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
EPHX2 P34913 1/20 0.44
USP5 P45974 3/20 0.43
ALDH1A1 P00352 5/20 0.43
POLB P06746 2/20 0.43
BCL2 P10415 1/20 0.42
BCL2L1 Q07817 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.42
CYP3A4 P08684 1/20 0.41
RECQL P46063 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2422850 0.88 MAPK9 (0.75) MAPK9MAPK10MEN1KMT2AEPHX2
SCHEMBL7886289 0.87 MAPK9 (0.65) MAPK9MAPK10MEN1KMT2AEPHX2
SCHEMBL2426655 0.86 MAPK9 (0.66) MAPK9MAPK10MEN1KMT2AEPHX2
SCHEMBL2420939 0.84 MAPK9 (0.63) MAPK9MAPK10MEN1KMT2AEPHX2
SCHEMBL2426036 0.84 MAPK9 (0.64) MAPK9MAPK10MEN1KMT2AEPHX2
SCHEMBL27495526 0.83 MAPK9 (0.49) MAPK9MAPK10MEN1KMT2AUSP5
SCHEMBL4972085 0.83 MAPK9 (0.68) MAPK9MAPK10MEN1KMT2AEPHX2
SCHEMBL2428799 0.83 MAPK9 (0.61) MAPK9MAPK10MEN1KMT2AALDH1A1
SCHEMBL6437014 0.83 MAPK9 (0.65) MAPK9MAPK10MEN1KMT2AEPHX2
SCHEMBL1518918 0.83 MAPK9 (0.62) MAPK9MAPK10MEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012995-B1 Pharmaceutically active sulfonamide derivatives MERCK SERONO SA (CH) 2011-09-06 US claimed
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 US claimed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 US claimed
EP-1663193-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES Applied Research Systems ARS Holding N.V. (AN) 2006-06-07 EP claimed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 EP claimed
WO-2005025558-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2005-03-24 WO claimed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 CN claimed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 CN claimed
US-8658640-B2 JNK inhibitors for the treatment of endometriosis MERCK SERONO SA (CH) 2014-02-25 US disclosed
US-8592414-B2 JNK inhibitors for the treatment of endometriosis Merck Serono, S.A. (CH) 2013-11-26 US disclosed
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-24 US disclosed
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-10 US disclosed
US-8012995-B1 Pharmaceutically active sulfonamide derivatives MERCK SERONO SA (CH) 2011-09-06 US disclosed
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 US disclosed
US-20090176761-A1 JNK Inhivitors for the Treatment of Endometriosis LABORATORIES SERONO SA (CH) 2009-07-09 US disclosed
US-20080039377-A1 Composition Comprising a Jnk Inhibitor and Cyclosporin APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2008-02-14 US disclosed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 US disclosed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 EP disclosed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 CN disclosed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes CBR3, INSR, CS MAPK9 2768/4885MAPK10 1940/4885MEN1 3205/4885
US-20080039377-A1 Composition Comprising a Jnk Inhibitor and Cyclosporin LCK, MAPKAPK2, MAP3K20 MAPK9 36/4885MAPK10 40/4885MEN1 1582/4885
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN MAPK9 49/4885MAPK10 40/4885MEN1 3898/4885
US-20090176761-A1 JNK Inhivitors for the Treatment of Endometriosis MAPKAPK2, MAP3K20, MAP3K6 MAPK9 35/4885MAPK10 26/4885MEN1 4390/4885
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN MAPK9 49/4885MAPK10 40/4885MEN1 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.